LB PHARMACEUTICALS INC

LB Pharmaceuticals Inc. announced an equity award grant to Christopher Zergebel, its new Senior Vice President, Clinical Operations. The award, an inducement grant under Nasdaq rules, consists of an option to purchase 75,000 shares of common stock at an exercise price of $32.95 per share. The option vests over four years, with 25% vesting on the first anniversary and the remainder monthly thereafter, subject to continuous service. The company is a late-stage biopharmaceutical company developing LB-102 for neuropsychiatric disorders.

LB Pharmaceuticals Inc announced the appointment of Christopher Zergebel as Senior Vice President, Clinical Operations. Mr. Zergebel brings over 25 years of global development operations experience, including his previous role as VP at Cellectis Biologics. He will be instrumental in advancing the company's lead product candidate, LB-102, which currently has Phase 3 and Phase 2 trials underway for schizophrenia and bipolar depression, respectively, with another Phase 2 trial planned for adjunctive major depressive disorder.

LB Pharmaceuticals Inc. announced that Anna Eramo, M.D., resigned from her position as Chief Medical Officer, effective June 15, 2026, for personal reasons. Dr. Eramo will transition to an advisor role on June 16, 2026, and will provide full-time consulting services until September 15, 2026. The company stated that her departure is not related to clinical program operations and is not expected to materially impact clinical development activities or milestones. In connection with her resignation, Dr. Eramo entered into a separation and consulting agreement, which includes continued base salary, a prorated 2026 annual bonus, accelerated vesting of 66,143 stock options, and COBRA reimbursement.

LB Pharmaceuticals Inc announced that its executive team will present and participate in two upcoming investor conferences. The company will present at the Jefferies Global Healthcare Conference on June 4, 2026, and participate in the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 16, 2026. Webcasts and replays of the presentations will be accessible on the company's investor relations website.

LB Pharmaceuticals reported a net loss of $19.1 million for Q1 2026, an increase from $5.3 million in Q1 2025, driven by significantly higher research and development expenses. The company successfully completed a private placement in February 2026, raising $93.8 million in net proceeds, bolstering its cash position to $365.6 million. During the quarter, LB Pharmaceuticals initiated Phase 2 and Phase 3 clinical trials for its lead product candidate, LB-102, for bipolar 1 depression and acute schizophrenia, respectively.

LB Pharmaceuticals Inc. reported a net loss of $19.1 million for the first quarter ended March 31, 2026, with research and development expenses increasing to $14.6 million. The company initiated pivotal Phase 3 and Phase 2 clinical trials for LB-102 in schizophrenia and bipolar depression, respectively, and plans a Phase 2 trial for adjunctive MDD in early 2027. Following a $100 million private placement, LB Pharmaceuticals holds $365.6 million in cash, cash equivalents, and marketable securities, expected to fund operations into Q2 2029 through multiple clinical milestones.

LB Pharmaceuticals announced its first quarter 2026 financial results and provided a corporate update. The company initiated the pivotal Phase 3 NOVA-2 trial for schizophrenia and the Phase 2 ILLUMINATE-1 trial for bipolar depression, with plans for a Phase 2 trial in adjunctive MDD. Cash, cash equivalents, and marketable securities stood at $365.6 million as of March 31, 2026, expected to fund operations into Q2 2029. The net loss for the quarter was $19.1 million, reflecting increased R&D expenses for advancing its clinical pipeline, supported by a recent $100 million private placement.

LB Pharmaceuticals announced the publication of positive Phase 2 NOVA-1 trial results for LB-102 in acute schizophrenia in JAMA Psychiatry. The trial demonstrated statistically significant benefits, rapid onset, sustained effect, and a favorable safety profile. LB-102 is currently in a pivotal Phase 3 NOVA-2 trial for schizophrenia, with topline data expected in 2H 2027, and is also being evaluated for bipolar depression and adjunctive major depressive disorder.

LB Pharmaceuticals Inc (LBRX) announced that its Chief Executive Officer, Heather Turner, will present at the 25th Annual Needham Virtual Healthcare Conference. The presentation is scheduled for Thursday, April 16, 2026, at 11:45 a.m. ET. This event provides an opportunity for the company to engage with institutional investors and highlight its progress in developing novel therapies for neuropsychiatric diseases, including its lead product candidate, LB-102. A live webcast and archived replay of the presentation will be accessible on the company's investor relations website.